CTEP Branches and Offices
Last Updated: 03/01/16
News Releases
- TAILORx Trial Shows Some Women with Breast Cancer May Forgo Chemotherapy (Posted: 9/28/15)
- NCI-MATCH trial will link targeted cancer drugs to gene abnormalities (Posted: 6/1/15)
- New analysis of breast cancer subtypes could lead to better risk stratification; Annual Report to the Nation shows that mortality and incidence for most cancers continue to decline (Posted 3/30/15)
- Exceptional Responders Initiative: Questions and Answers (Posted: 3/23/15)
- NIH exceptional responders to cancer therapy study launched (Posted: 9/24/14)
- NIH announces the launch of 3 integrated precision medicine trials; ALCHEMIST is for patients with certain types of early-stage lung cancer (Posted: 8/18/14)
- ALCHEMIST (The Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials): Questions and Answers (Posted: 8/18/14)
- Lung-MAP Launches: First Precision Medicine Trial From National Clinical Trials Network (Posted: 6/16/14)
- Statement on Forthcoming Changes in NCI's Clinical Trials Programs (Posted: 4/4/14)
- Adding chemotherapy following radiation treatment improves survival for adults with a slow-growing type of brain tumor (Posted: 2/3/14)
About the Branch Chief
Meg Mooney, MD, MS, is the Associate Director of the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis (DCTD), at the National Cancer Institute (NCI), and she is also the Chief of the Clinical Investigations Branch (CIB) in CTEP.
More…